Name: Elon Musk Praises Novo Nordisk's Weight-Loss Drug Ozempic as Solution to Childhood Obesity Epidemic
Brand: benzinga.com
SKU: benzinga-com-64
Availability: OnlineOnly

critic

Elon Musk Praises Novo Nordisk's Weight-Loss Drug Ozempic as Solution to Childhood Obesity Epidemic

preview

Tesla (NASDAQ: TSLA) and SpaceX CEO Elon Musk has sparked a conversation about childhood obesity and potential solutions after giving his seal of approval for Novo Nordisk’s (NYSE: NVO) Ozempic, a GLP-1 agonist primarily prescribed to manage type 2 diabetes.
What Happened
On Sunday, Musk responded to a post on&nbsp;X&nbsp;about childhood obesity in the U.S. and Japan. The post by&nbsp;Calley Means,&nbsp;co-founder of health startup&nbsp;Truemed,&nbsp;suggested five policies to address the issue, including banning TV pharma ads and reforming agriculture subsidies.
It was re-shared by billionaire investor&nbsp;Bill Ackman, who tagged&nbsp;Joe Biden,&nbsp;Donald Trump, and&nbsp;Robert Kennedy Jr.&nbsp;— the three major presidential candidates for the 2024 elections, saying, “This is great advice.”
Musk responded to Ackman’s post, saying, “Ozempic&nbsp;ftw,” indicating his support for the drug.
Ozempic ftw 🤷‍♂️
— Elon Musk (@elonmusk) May 5, 2024
Also Read: Global Obesity Drug Market to Grow 16x – Top Weight-Loss Stocks to Watch in 2024
Why it Matters
Musk’s tweet has brought attention to the growing issue of childhood obesity in the U.S. and Japan.&nbsp;Obesity has been a significant&nbsp;public health concern, with long-term implications for the affected individuals and the healthcare system.
This is not the first time the tech mogul has seemingly backed the blockbuster drug. Last year, Musk claimed that Ozempic&nbsp;was affecting food sales at Walmart (NYSE: WMT).
In March, Novo Nordisk announced the&nbsp;launch of Ozempic’s sister drug,&nbsp;Wegovy, in Japan, in response to the country’s rising obesity rates. However, the drug has also faced criticism for its high cost.
Previously, Senator&nbsp;Bernie Sanders&nbsp;(I-Vt.) expressed concerns about the&nbsp;high price of Ozempic, which is sometimes used controversially for weight loss by suppressing appetite.
Earlier, the World Health Organization or WHO also cautioned that relying solely on potent and widely used medications for obesity won’t adequately tackle the escalating global obesity epidemic, which currently impacts more than a billion people.
Shares of Novo Nordisk closed today at $124.59, up +1.24%. YTD, NVO stock is up +22.02% and over the past year is up +47.93%. All-time, NVO shares have increased by +49,736%.
This article was originally published on Benzinga.com.
Join the Discussion in the WVC Facebook Investor Group
Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.com
Disclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.

Tesla (NASDAQ: TSLA) and SpaceX CEO Elon Musk has sparked a conversation about childhood obesity and potential solutions after giving his seal of approval for Novo Nordisk’s (NYSE: NVO) Ozempic, a GLP-1 agonist primarily prescribed to manage type 2 diabetes.
What Happened
On Sunday, Musk responded to a post on&nbsp;X&nbsp;about childhood obesity in the U.S. and Japan. The post by&nbsp;Calley Means,&nbsp;co-founder of health startup&nbsp;Truemed,&nbsp;suggested five policies to address the issue, including banning TV pharma ads and reforming agriculture subsidies.
It was re-shared by...

public

Ananya Gairola

Real-Time News ➡️  http://pro.benzinga.com. Data APIs ➡️  licensing@benzinga.com Founder @jasonraznick

benzinga.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Elon Musk Praises Novo Nordisk's Weight-Loss Drug Ozempic as Solution to Childhood Obesity Epidemic

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS